MOSCOW – In a groundbreaking medical advancement, Russian scientists have announced that a new mRNA cancer vaccine is ready for clinical application, according to Sputnik News. Developed by the Russian Federal Medical and Biological Agency (FMBA), the innovative vaccine named Enteromix has successfully passed preclinical trials, proving both highly effective and safe.
FMBA head Veronika Skvortsova revealed that Enteromix has shown remarkable results, including significant reduction in tumor size and slowing down tumor growth. Importantly, the vaccine has also been confirmed as safe for repeated use.
What makes Enteromix especially promising is its personalized approach—the vaccine will be tailored to each patient’s unique RNA profile. The first version will target colorectal cancer, while further variants are under development to combat glioblastoma, an aggressive brain tumor, and melanoma, a dangerous type of skin cancer.
This pioneering step highlights Russia’s growing role in the global race to develop next-generation mRNA cancer vaccines that could revolutionize cancer treatment worldwide.
